Free Express Shipping on Orders $450+ | Peptide of the Week: Tirzepatide - 10% Off This Week
Free Express Shipping on Orders $450+ | Peptide of the Week: Tirzepatide - 10% Off This Week
SNAP-8, also known as Acetyl Octapeptide-3, is a synthetic eight-amino-acid peptide derived from SNAP-25, a key protein involved in synaptic vesicle fusion and neurotransmitter release. In research settings, it is primarily studied for its ability to modulate SNARE complex formation at neuromuscular junctions, with applications in neuromuscular signaling models, topical peptide delivery systems, and dermal research. This 2026 guide covers the molecular profile, proposed mechanisms, research applications, and evidence context of SNAP-8 based on published scientific literature.
SNAP-8 (Acetyl Octapeptide-3) is a synthetic octapeptide derived from SNAP-25, a protein essential to SNARE complex assembly and neurotransmitter vesicle release. It is studied as a competitive inhibitor of SNARE complex formation, reducing acetylcholine release at neuromuscular junctions in localized, reversible, and non-toxic research models. CAS number: 868844-74-0. Molecular weight: approximately 951.08 g/mol. It is not a neurotoxin and is mechanistically distinct from botulinum toxin.
SNAP-8 belongs to a class of research peptides that target neurotransmission at the cellular level rather than systemic hormonal or repair pathways. Its mechanism centers on the SNARE complex, a protein assembly responsible for allowing neurotransmitter vesicles to fuse with cell membranes and release signaling molecules such as acetylcholine.
SNAP-8 is a lab-made peptide designed to interfere with how nerve cells signal muscles to contract. It does this by mimicking part of a key protein involved in neurotransmitter release, temporarily disrupting the signaling assembly at a very local level. The effect is localized and reversible. SNAP-8 is not a toxin and does not permanently alter signaling proteins the way botulinum toxin does.
This makes SNAP-8 mechanistically distinct from systemic peptides such as BPC-157, TB-500, or MOTS-C. Its research context is localized neuromuscular signaling, topical peptide delivery, and dermal models rather than systemic repair, endocrine, or immune biology.
SNAP-8 has a well-defined chemical identity confirmed across published research literature and cosmetic peptide science databases.
SNAP-8's mechanism is centered on competitive interference with SNARE complex assembly, which governs neurotransmitter vesicle fusion and release at neuromuscular junctions.
The SNARE complex is a protein assembly responsible for allowing neurotransmitter-filled vesicles to fuse with the cell membrane and release their contents, including acetylcholine. Its three core components are SNAP-25, Syntaxin, and VAMP (synaptobrevin). Disruption of SNARE complex assembly reduces the rate and extent of vesicle fusion and neurotransmitter release.
| Mechanism Step | What Happens | Research Significance |
|---|---|---|
| SNAP-25 Mimicry | SNAP-8 mimics a fragment of the SNAP-25 protein, the same protein that forms part of the SNARE complex required for vesicle fusion. | By presenting a competing fragment, SNAP-8 occupies the binding sites that would otherwise be used by native SNAP-25 to form the full SNARE complex. |
| Competitive SNARE Inhibition | SNAP-8 disrupts complete SNARE complex assembly by competing with SNAP-25 for its position in the complex. | An incomplete or destabilized SNARE complex reduces the efficiency of vesicle-membrane fusion, resulting in reduced neurotransmitter release. |
| Reduced Acetylcholine Release | With SNARE assembly partially inhibited, acetylcholine release at the neuromuscular junction is reduced in a dose-dependent manner in studied models. | Acetylcholine is the neurotransmitter responsible for triggering muscle contraction. Reduced release means reduced contraction signaling, which is why SNAP-8 is studied in expression-related muscle models. |
| Reversibility | SNAP-8 does not cleave or permanently alter SNARE proteins. The effect is competitive and reversible as the peptide degrades or is cleared. | This reversibility is a defining distinction from botulinum toxin, which achieves SNARE disruption through irreversible protein cleavage. |
| Localized Activity | In topical and dermal research models, SNAP-8 is applied to specific areas rather than systemically administered. | Localized delivery limits systemic exposure and focuses the mechanism on target neuromuscular sites, making it relevant primarily to surface-level and dermal research models. |
Understanding SNAP-8 requires a clear comparison with the proteins and agents it is often discussed alongside in the neuromuscular signaling literature.
| Feature | SNAP-8 (Acetyl Octapeptide-3) | SNAP-25 (Native Protein) | Botulinum Toxin |
|---|---|---|---|
| Type | Synthetic octapeptide (8 amino acids) | Natural endogenous protein (206 amino acids) | Bacterial neurotoxin |
| Role in SNARE biology | Competitive inhibitor of SNARE complex assembly | Essential structural component of the SNARE complex | Cleaves SNARE proteins (including SNAP-25) to prevent assembly |
| Mechanism | Competes with SNAP-25 for SNARE complex binding sites, reducing assembly efficiency | Forms part of the functional SNARE complex that enables vesicle fusion | Proteolytically cleaves SNAP-25 and/or VAMP, permanently preventing SNARE function |
| Potency | Low, localized effect in studied models | N/A (endogenous structural protein) | Extremely high neurotoxic potency |
| Reversibility | Yes, reversible competitive inhibition | N/A | No, permanent until new SNARE protein is synthesized (weeks to months) |
| Toxicity | No known toxic classification in research contexts | N/A (endogenous protein) | Highly toxic; lethal at nanogram-per-kilogram doses |
| Primary research context | Topical neuromuscular signaling models, dermal research, in vitro peptide delivery | Neuroscience, synaptic biology, vesicle fusion research | Medical neurotoxin applications, neuromuscular disease research |
SNAP-8 is studied across a specific set of experimental contexts. All current research is localized and topical in nature rather than systemic.
| Research Area | Study Context | Nature of Findings |
|---|---|---|
| Neuromuscular Signaling Models | In vitro SNARE complex inhibition | SNAP-8 is studied in vitro for its ability to modulate neurotransmitter release and synaptic signaling pathways through competitive SNARE interference. These models establish the mechanistic basis for its research interest. |
| Topical and Dermal Research | Expression-related muscle contraction pathways | Most published research focuses on topical peptide delivery systems examining expression-related muscle contraction signaling, surface-level neuromodulation, and repeated-application models in dermal contexts. |
| Cosmetic Peptide Science | Peptide formulation and efficacy research | SNAP-8 is frequently cited in cosmetic peptide research as an example of a neuromodulatory peptide. Review literature on cosmetic peptides covers its proposed mechanism alongside other SNARE-targeting compounds. |
| Peptide Delivery System Research | Skin penetration and carrier formulation studies | SNAP-8 is studied in formulations examining skin penetration efficiency, stability of short-chain peptides in topical vehicles, and carrier systems including liposomes and emulsions. |
| Comparative SNARE Biology | Mechanistic studies alongside other SNARE-targeting agents | Some research positions SNAP-8 within the broader class of SNARE-targeting peptides, comparing its potency, reversibility, and specificity with other competitive inhibitors and with botulinum toxin in controlled in vitro settings. |
SNAP-8 occupies a distinct category within peptide research. Understanding where it sits in the broader landscape helps researchers apply it correctly.
| Feature | SNAP-8 | Systemic Peptides (e.g., BPC-157, TB-500, MOTS-C) |
|---|---|---|
| Mechanism type | Structural: SNARE complex competitive inhibition | Varies: receptor signaling, immune modulation, mitochondrial biology, tissue repair |
| Biological target | Neuromuscular junction, synaptic vesicle fusion machinery | Systemic receptors, immune cells, vascular and tissue-repair pathways |
| Research delivery | Topical, localized, in vitro | Typically subcutaneous or intravenous injection in preclinical and clinical studies |
| Scope of effect | Highly localized, surface-level neuromodulation | Systemic or multi-tissue effects studied across organs and systems |
| Reversibility | Yes, fully reversible competitive inhibition | Varies by compound and mechanism |
| Primary research domain | Dermal science, neuromuscular signaling, peptide delivery systems | Immunology, tissue repair, endocrinology, metabolic biology |
As a short-chain synthetic peptide studied primarily in topical delivery systems, SNAP-8 requires careful handling to maintain sequence integrity and formulation performance.
| Parameter | Standard | Research Significance |
|---|---|---|
| Lyophilized storage | -20°C | Standard lyophilized peptide storage preserves the octapeptide sequence before reconstitution or formulation. |
| Working solution storage | 2-8°C | Once reconstituted or incorporated into a carrier vehicle, keep refrigerated and use within the appropriate research window. |
| Freeze-thaw cycles | Minimize | Repeated freeze-thaw cycles can degrade short-chain peptide integrity and reduce formulation consistency across experimental replicates. |
| Environmental exposure | Avoid heat, light, and moisture | All three accelerate peptide degradation, which is especially relevant for topical formulations where stability in the delivery vehicle also needs to be maintained. |
| Carrier system compatibility | Evaluate per formulation | Research into SNAP-8 delivery often examines liposomal, emulsion-based, and encapsulated systems. Compatibility with the carrier must be assessed for each specific formulation in research contexts. |
For a compound studied primarily in topical delivery systems and in vitro models, purity and identity verification are directly relevant to research validity and formulation consistency.
| Standard | Why It Matters for SNAP-8 Research |
|---|---|
| Third-party HPLC testing | Confirms purity of the octapeptide sequence and identifies any chromatographic impurities that could interfere with SNARE inhibition experiments or topical delivery studies. |
| Mass spectrometry identity confirmation | Verifies the molecular weight and sequence identity of the acetylated octapeptide. Identity confirmation is especially important for SNARE-targeting peptides where structural specificity determines mechanism. |
| Batch-specific COA availability | Lot-level traceability ensures researchers can document the exact material used across studies and track formulation performance across batches. |
| 99%+ purity threshold | Impurities in topical peptide delivery research can affect skin penetration data, carrier compatibility, and in vitro signaling results, making high purity essential for reproducible outcomes. |
| Research-use-only labeling | Ensures correct regulatory framing as a laboratory material in both Canada and the USA. |
These pages extend the topical peptide, neuromuscular signaling, and Canadian research quality context surrounding SNAP-8.
These answers cover the most common SNAP-8 research and sourcing questions from researchers in Canada and the USA in 2026.
SNAP-8 (Acetyl Octapeptide-3) is a synthetic eight-amino-acid peptide derived from SNAP-25, a key protein in SNARE complex assembly and neurotransmitter vesicle release. CAS number: 868844-74-0. Molecular weight: approximately 951.08 g/mol. It is studied as a competitive inhibitor of SNARE complex formation, with applications in neuromuscular signaling models and topical peptide delivery research.
SNAP-8 mimics a fragment of SNAP-25 and competes with the native protein for binding sites in the SNARE complex. By disrupting SNARE complex assembly, it reduces the efficiency of neurotransmitter vesicle fusion with the cell membrane, resulting in reduced acetylcholine release at the neuromuscular junction in studied models. The effect is competitive and reversible.
SNAP-8 and botulinum toxin are mechanistically related in that both affect SNARE-mediated neurotransmitter release, but they are fundamentally different. Botulinum toxin is a highly potent neurotoxin that permanently cleaves SNARE proteins through proteolytic action. SNAP-8 is a non-toxic synthetic peptide that temporarily and reversibly competes with SNAP-25 for SNARE complex assembly. SNAP-8 is not a neurotoxin and does not permanently alter any protein.
No. SNAP-8 has no known toxic classification in research contexts. It is a synthetic research peptide with a reversible, competitive mechanism. Its effects are localized and temporary. It does not carry the toxicity profile associated with botulinum toxin or other neurotoxins.
SNAP-8 is studied in neuromuscular signaling models and topical peptide delivery research. Published research focuses on expression-related muscle contraction pathways, in vitro SNARE complex inhibition, skin penetration and carrier system formulations, and comparative SNARE biology. It is not studied for systemic effects.
No. Research on SNAP-8 is primarily localized and topical in nature. It is mechanistically distinct from systemic peptides and should not be studied or interpreted within systemic research frameworks. Its research context is neuromuscular signaling at the local level, dermal models, and in vitro peptide delivery systems.
All Luxara Labs peptides, including SNAP-8, are tested to a minimum of 99% purity by independent third-party HPLC and mass spectrometry analysis. A batch-specific Certificate of Analysis (COA) is available for every order. Verification is performed by independent labs before any product is released.
The following peer-reviewed references support the SNARE biology, neuromuscular signaling, and cosmetic peptide content discussed on this page. All links direct to verified primary sources.
Join our list and get an instant 10% discount code — valid for first-time buyers.
